<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01469481</url>
  </required_header>
  <id_info>
    <org_study_id>B2611007</org_study_id>
    <nct_id>NCT01469481</nct_id>
  </id_info>
  <brief_title>Single Dose Study To Study The Absorption, Metabolism And Excretion Of PF-04991532</brief_title>
  <official_title>An Open Label, Single-Period, Phase 1 Study To Evaluate The Pharmacokinetics, Excretion, Mass Balance And Metabolism Of [14c]-PF-04991532 In Healthy Adult Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the excretion balance, metabolic profile and the
      routes of excretion of [14C]PF-04991532 in healthy adult male subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mass Balance: Urinary and fecal excretion of radioactivity over time expressed as a percentage of the total radioactive dose administered.</measure>
    <time_frame>0-168 hrs</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Metabolic Profiling/identification and determination of relative abundance of PF-04991532 and the metabolites of PF-04991532 in plasma, urine, and feces.</measure>
    <time_frame>0-168 hrs</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>radioactivity AUC</measure>
    <time_frame>0-168 hrs</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>plasma PF-04991532 AUC</measure>
    <time_frame>0-168 hrs</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>radioactivity Cmax</measure>
    <time_frame>0-168 hrs</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>plasma PF-04991532 Cmax</measure>
    <time_frame>0-168 hrs</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>plasma PF-04991532 Tmax</measure>
    <time_frame>0-168 hrs</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>radioactivity Tmax</measure>
    <time_frame>0-168 hrs</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>plasma PF-04991532 t1/2</measure>
    <time_frame>0-168 hrs</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>radioactivity t1/2</measure>
    <time_frame>0-168 hrs</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04991532</intervention_name>
    <description>a single oral dose of [14C]PF-04991532 (450 mg/100 uCi suspension)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subjects between the ages of 18 and 55 years, inclusive (Healthy is
             defined as no clinically relevant abnormalities identified by a detailed medical
             history, full physical examination, including blood pressure and pulse rate
             measurement, 12-lead ECG and clinical laboratory tests).

          -  Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight &gt;50 kg(110 lbs).

          -  An informed consent document signed and dated by the subject.

        Exclusion Criteria:

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
             allergic disease (including drug allergies, but excluding untreated, asymptomatic,
             seasonal allergies at time of dosing) or clinical findings at Screening.

          -  History of irregular bowel movements (eg, irritable bowel syndrome or frequent
             episodes of diarrhea or constipation).

          -  Any condition possibly affecting drug absorption (eg, appendectomy, gastrectomy).
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98418</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B2611007&amp;StudyName=Single%20Dose%20Study%20To%20Study%20The%20Absorption%2C%20Metabolism%20And%20Excretion%20Of%20PF-04991532</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 28, 2011</study_first_submitted>
  <study_first_submitted_qc>November 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2011</study_first_posted>
  <last_update_submitted>January 27, 2012</last_update_submitted>
  <last_update_submitted_qc>January 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diabetes mellitus</keyword>
  <keyword>ADME</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

